Figure 3

ASFV-Gluc/EGFP is genetically stable. A and B Stability of EGFP expression. rASFV-Gluc/EGFP was subjected to 20 consecutive passages in PAMs, and EGFP expression was observed by fluorescence microscopy at 72 hours post-infection (hpi) for P1 and P20, with representative fluorescence images captured (A) and the number of EGFP-positive cells per field of view counted using the ImageJ software (B). Scale bars = 400 μm. C Stability of the Gluc activities. rASFV-Gluc/EGFP was subjected to 20 consecutive passages in PAMs, and Gluc activities were assayed at P1 and P20 at 72 hpi. D and E Stability of the hemadsorpting capability. rASFV-Gluc/EGFP was subjected to 20 consecutive passages in PAMs, fresh porcine red blood cells were added to P1 and P20 at 72 hpi, and hemadsorption was observed (D). The number of hemadsorption-positive cells per field of view was measured using the ImageJ software (E). Red arrows indicate hemadsorption. Scale bars = 400 μm. F and G NGS analysis of the complete genome of rASFV-Gluc/EGFP. A complete genome coverage plot using the NGS reads of rASFV-Gluc/EGFP (F) and rASFV-Gluc/EGFP-P20 (G) was generated by mappingvia mapping against the ASFV-WT genome. The read coverage was analysed using SAMtools (version 1.3.1) and visualized using RStudio software (version 3.6.1). ****P < 0.0001; ns, not significant.